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Abstract The International Consensus on ANA Patterns
(ICAP) was initiated as a workshop aiming to thoroughly
discuss and achieve consensus regarding the morphological
patterns observed in the indirect immunofluorescence assay
on HEp-2 cells. One of the topics discussed at the second
ICAP workshop, and addressed in this paper, was the
harmonization of reporting ANA test results. This discus-
sion centered on the issue if cytoplasmic and mitotic pat-
terns should be reported as positive or negative. This report
outlines the issues that impact on two major different
reporting methods. Although it was appreciated by all
participants that cytoplasmic and mitotic patterns are
clinically relevant, implications for existing diagnos-
tic/classification criteria for ANA-associated diseases in
particular hampered a final consensus on this topic.
Evidently, a more concerted action of all relevant stake-
holders is required. Future ICAP workshops may help to
facilitate this action.
Keywords Anti-nuclear antibodies  Indirect
immunofluorescence  Nuclear patterns  Cytoplasmic
patterns  Mitotic patterns  Harmonization
Introduction
Antinuclear antibodies (ANA) are important elements in
the diagnosis of a variety of autoimmune diseases, espe-
cially ANA-associated rheumatic diseases (AARD) [1–3].
While ANA originally were detected by indirect
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immunofluorescence (IIF) [4], several alternative methods
have entered the market [5]. Although this has raised many
discussions on the definition and positioning of ANA
testing [6–8], ANA detection by IIF has the advantage of
obtaining information on the IIF staining pattern, which is
considered of added clinical value. The introduction of
HEp-2 cells as the substrate for ANA IIF has increased the
awareness that, besides nuclear patterns, cytoplasmic and
mitotic cell patterns can also be recognized. As such, the
term anti-cellular antibodies has been suggested to
encompass the wider spectrum of these autoantibodies [8,
9]. However, because the use of the acronym ANA is
firmly established and universally used, replacement by an
alternative terminology will not be easy. Changes in
nomenclature would have many implications, for instance
for existing guidelines, disease criteria, external quality
control programs, education, and reimbursement policies.
The International Consensus on ANA Patterns (ICAP)
initiative started in 2014 as a workshop parallel to the 12th
International Workshop on Autoimmunity and Autoanti-
bodies (IWAA) in Sao Paulo, Brazil [10]. This first ICAP
workshop was devoted to establishing a consensus on the
nomenclature of the distinct ANA patterns recognized by
IIF on HEp-2 cells. This resulted in a classification tree that
distinguishes three major IIF staining categories: nuclear,
cytoplasmic and mitotic patterns [11]. The second ICAP
workshop was recently hosted in conjunction with the 12th
Dresden Symposium on Autoantibodies in Dresden, Ger-
many. Since it was recognized that standardization and
harmonization in autoimmune diagnostics is of utmost
importance, part of the discussion was focused on the
reporting of ANA results. The discussion was prepared in
advance by Carlos von Mu¨hlen (Brazil), Ignacio Garcia De
La Torre (Mexico), and Jan Damoiseaux (The Nether-
lands). The input included a number of (inter)national
recommendations on this topic [1, 6, 8, 9, 12–18] and two
proposals.
Here we register the discussion with a focus on two
main points regarding the articulation of the ANA report:
(1) the position of cytoplasmic and mitotic patterns, i.e., are
they to be reported as ANA negative or ANA positive; and
(2) the advice to clinicians on the possible significance of
the patterns observed, i.e., possibly involved autoantibodies
and associated diseases.
(Inter)National recommendations on ANA reporting
A non-exhaustive review of the currently available rec-
ommendations on reporting ANA results is provided in
Table 1. It was generally agreed that the report should
contain information on the type of immunoassay that has
been used. On the other hand, if an ANA pattern is
reported, this implies that ANA were determined by IIF
because alternative methods do not allow pattern recogni-
tion. Surprisingly, almost none of the recommendations
made a statement on reporting ANA simply as negative or
positive. In the case of ANA IIF, again this may be sur-
passed by providing a titer and/or pattern. However, in
relation to the discussion whether a cytoplasmic or mitotic
apparatus staining pattern is to be considered ANA posi-
tive, a straightforward interpretation in terms of ‘‘ANA
negative’’ or ‘‘ANA positive’’ was thought to be helpful. In
Argentina, Belgium and Brazil, it is recommended that
results for distinct cellular compartments are reported, but
this does not unequivocally imply that a cytoplasmic/mi-
totic apparatus reactivity is to be considered ANA positive
[9, 16, 18]. In the second Brazilian consensus on ANA in
HEp-2 cells, however, it was decided that cytoplasmic
patterns are to be considered ANA positive, but a subtitle is
to be added to the report, stating that ‘‘ANA is actually a
test that detects autoantibodies to cellular antigens—thus
encompassing the whole cellular anatomy and all cellular
structures’’ [9]. Also, the Italian recommendations of the
Forum Interdisciplinare per la Ricerca nelle Mallattie
Autoimmuni (FIRMA) explicitly state that a cytoplasmic
pattern is to be considered ANA positive (http://www.
gruppofirma.com). Neither the ACR nor the EASI/IUIS
recommendations state a clear position towards cytoplas-
mic/mitotic apparatus patterns being considered ANA
negative or positive [1, 6, 8]. The EASI/IUIS recommen-
dation only states ‘‘besides nuclear patterns also cytoplas-
mic and mitotic apparatus patterns should be reported and
specified when possible’’ [8]. Finally, the European Con-
sensus Finding Study Group on Laboratory Investigation in
Rheumatology (ECGSG), being part of the European
League Against Rheumatism (EULAR), considers a cyto-
plasmic pattern as ANA negative (personal communication
Johan Ro¨nnelid, Sweden).
Recommendations about titer and pattern are obviously
restricted to the IIF method for ANA detection. Titration is
considered clinically relevant since a higher titer is asso-
ciated with a higher positive likelihood ratio to confirm a
diagnosis of an AARD [19, 20]. Furthermore, a higher titer
also increases the chance of identifying the antigen that is
recognized in the ANA IIF test by antigen-specific
immunoassays [21, 22]. These findings, however, are
challenged by the introduction of newer technologies. The
added value of extremely high titers is considered to be
limited as can be concluded from the fact that in several
recommendations an end-point titer is defined beyond
which no further dilutions are needed. Nevertheless, both
the ACR and EASI/IUIS recommendations advised to
perform an end-point titration [1, 8]. Alternatively, the
Dutch and Italian recommendations allow reporting fluo-
rescence intensity instead of the titer [13; http://www.
gruppofirma.com]. This option may be valuable as some of
1 Page 2 of 8 Autoimmun Highlights (2016) 7:1
123
T
a
b
le
1
(I
n
te
r)
N
at
io
n
al
re
co
m
m
en
d
at
io
n
s
o
n
th
e
re
p
o
rt
in
g
o
f
A
N
A
te
st
re
su
lt
s
A
rg
en
ti
n
a
[1
8
]
A
u
st
ri
a
[1
7
]
B
el
g
iu
m
[1
6
]
B
ra
zi
l
[9
]
G
er
m
an
y
[1
2
]
It
al
y
(F
IR
M
A
)
N
et
h
er
la
n
d
s
[1
0
]
A
C
R
[6
]
E
A
S
I/
IU
IS
[8
]
R
em
ar
k
A
N
A
m
et
h
o
d
?
?
a
N
S
?
N
A
b
N
A
b
?
a
?
?
a
a
T
es
ts
b
as
ed
o
n
a
re
st
ri
ct
ed
n
u
m
b
er
o
f
d
efi
n
ed
n
u
cl
ea
r
an
ti
g
en
s
ar
e
ex
cl
u
d
ed
b
R
ec
o
m
m
en
d
at
io
n
s
ar
e
re
st
ri
ct
ed
to
II
F
te
st
in
g
N
eg
/P
o
s
?
a
N
S
N
S
b
N
S
a
N
S
?
c
N
S
?
d
N
S
a
S
co
re
d
fo
r
al
l
ce
ll
u
la
r
co
m
p
ar
tm
en
ts
b
S
co
re
d
se
p
ar
at
el
y
fo
r
n
u
cl
ea
r
an
d
cy
to
p
la
sm
ic
st
ai
n
in
g
c
C
y
to
p
la
sm
ic
st
ai
n
in
g
is
co
n
si
d
er
ed
A
N
A
p
o
si
ti
v
e
d
In
cl
u
d
in
g
%
co
n
tr
o
ls
w
it
h
si
m
il
ar
ti
te
r
T
it
er
(e
n
d
-t
it
er
)
?
a
?
(1
:1
2
8
0
)
?
(1
:5
0
0
0
)
?
(1
:6
4
0
)
?
(1
:5
1
2
0
)
?
b
?
a
?
c
?
c
a
E
n
d
-t
it
er
is
n
o
t
d
efi
n
ed
b
T
it
ra
ti
o
n
is
o
p
ti
o
n
al
;
st
ai
n
in
g
in
te
n
si
ty
is
al
te
rn
at
iv
e
c
T
it
ra
ti
o
n
to
h
ig
h
es
t
d
il
u
ti
o
n
P
at
te
rn
?
a
?
a
?
b
?
a
?
?
?
c
N
S
?
a
a
In
cl
u
d
in
g
cy
to
p
la
sm
ic
an
d
m
it
o
ti
c
p
at
te
rn
s
b
A
t
le
as
t
ce
n
tr
o
m
er
e
an
d
cy
to
p
la
sm
ic
p
at
te
rn
s
c
R
ep
o
rt
in
g
to
th
e
cl
in
ic
ia
n
is
o
p
ti
o
n
al
A
d
v
is
e
re
fl
ex
te
st
in
g
N
S
N
S
?
a
N
S
?
b
?
c
?
c
?
c
?
c
a
O
n
ly
if
A
N
A
is
p
o
si
ti
v
e
b
M
en
ti
o
n
p
o
ss
ib
le
ta
rg
et
an
ti
g
en
s
c
If
A
N
A
is
p
o
si
ti
v
e
o
r
d
is
ea
se
as
so
ci
at
ed
w
it
h
an
ti
-S
S
A
,
-J
o
1
(o
r
o
th
er
sy
n
th
et
as
es
)
an
d
/o
r
-R
ib
P
is
su
sp
ec
te
d
A
d
v
is
e
d
is
ea
se
as
so
ci
at
io
n
N
S
N
S
N
S
?
?
a
N
S
N
S
N
S
N
S
a
In
li
g
h
t
o
f
d
ia
g
n
o
st
ic
q
u
es
ti
o
n
p
o
se
d
R
efl
ex
te
st
in
g
m
ay
b
e
ei
th
er
in
te
g
ra
te
d
in
a
te
st
in
g
al
g
o
ri
th
m
o
r
ad
v
is
ed
to
d
o
so
A
C
R
A
m
er
ic
an
C
o
ll
eg
e
o
f
R
h
eu
m
at
o
lo
g
y
,
A
N
A
an
ti
-n
u
cl
ea
r
an
ti
b
o
d
ie
s,
E
A
S
I
E
u
ro
p
ea
n
A
u
to
im
m
u
n
it
y
S
ta
n
d
ar
d
iz
at
io
n
In
it
ia
ti
v
e,
F
IR
M
A
F
o
ru
m
In
te
rd
is
ci
p
li
n
ar
e
p
er
la
R
ic
er
ca
n
el
le
M
al
la
tt
ie
A
u
to
im
m
u
n
i,
II
F
in
d
ir
ec
t
im
m
u
n
o
fl
u
o
re
sc
en
ce
,
IU
IS
In
te
rn
at
io
n
al
U
n
io
n
o
f
Im
m
u
n
o
lo
g
ic
al
S
o
ci
et
ie
s,
N
A
n
o
t
ap
p
li
ca
b
le
,
N
S
n
o
t
sp
ec
ifi
ed
Autoimmun Highlights (2016) 7:1 Page 3 of 8 1
123
the newer automated digital ANA reading systems score
the fluorescence intensity and even project end-point titers
on a single well dilution, and, importantly, these intensities
seem to correlate quite well with the end-point titers [5, 23,
24]. The relevance of reporting ANA patterns is under-
scored by all recommendations, except for the ACR rec-
ommendations. In the Netherlands, though, reporting can
be decided locally upon consultation with the clinicians
involved [10].
Finally, the recommendations differentially touch on the
issue of advice to be added for interpretation of the results
obtained. Although many laboratories use general remarks
with respect to possible disease associations, most recom-
mendations do not address this point. Only the Brazilian
consensus strongly recommends the inclusion of such
remarks in the ANA report [9], and in the German con-
sensus such advice is only provided in the light of the
diagnostic question posed [12]. There is, however, more
consensus about the recommendations in the context of
reflex testing. In Germany, it is recommended to mention
possible target antigens, based on the ANA pattern and the
clinical information provided [12]. Depending on the
reimbursement policies as determined by individual juris-
dictions, the reflex testing can be preempted in a testing
algorithm. In that case, advice about reflex testing is
redundant.
Two proposals for reporting of ANA test results
During the second ICAP workshop, two alternative rec-
ommendations for reporting of ANA test results were
discussed. These alternatives only differed with respect to
cytoplasmic and mitotic patterns being considered ANA
positive or negative (Fig. 1). In these proposals the report
should consist of 3 items: type of assay used, test result,
and, if appropriate, advice on reflex testing. These items
were chosen based on being the common denominator in
the examined (inter)national recommendations (Table 1).
Assay: ANA on HEp-2 cells
Result: Posive, cytoplasmic speckled, 1:80
Advice: In case of suspicion of myosis, consider further tesng
for an-synthetases, e.g. Jo-1
Assay: ANA on HEp-2 cells
Result: Negave
Advice: -
Assay: ANA on HEp-2 cells
Result: Negave, cytoplasmic speckled, 1:80
Advice: In case of suspicion of myosis, consider further tesng
for an-synthetases, e.g. Jo-1
Assay: ANA on HEp-2 cells
Result: Negave
Advice: -
Assay: ANA on HEp-2 cells
Result: Posive, nuclear speckled, 1:160 and cytoplasmic
recular/AMA, 1:1280
Advice: In case of suspicion of autoimmune liver disease, 
consider confirmaon of an-mitochondrial anbodies
Assay: ANA on HEp-2 cells
Result: Posive, nuclear speckled, 1:160 and cytoplasmic
recular/AMA, 1:1280
Advice: In case of suspicion of autoimmune liver disease, 
consider confirmaon of an-mitochondrial anbodies
Assay: ANA on HEp-2 cells
Result: Posive, centromere, 1:1280 and nuclear homogeneous, 
1:80
Advice: In case of suspicion of systemic sclerosis, consider
confirmaon of an-CENP-B anbodies
Assay: ANA on HEp-2 cells
Result: Posive, centromere, 1:1280 and nuclear homogeneous, 
1:80
Advice: In case of suspicion of systemic sclerosis, consider
confirmaon of an-CENP-B anbodies
Examples illustrang the recommendaons for reporng ANA test results
Proposal 1: cytoplasmic & mitoc paerns considered ANA posive Proposal 2: cytoplasmic & mitoc paerns considered ANA negave
A
B
C
D
Fig. 1 Examples illustrating the recommendations for reporting of
ANA test results. The report consists of three categories: the type of
assay used, the test results (positive/negative, pattern, and antibody
level), and the advice for the clinician. In proposal 1 (left),
cytoplasmic (and mitotic) patterns are considered ANA positive,
while in proposal 2 (right), cytoplasmic (and mitotic) patterns are
considered ANA negative. The examples shown illustrate alternate
possibilities according to the rules in each proposal for reporting
ANA test results. If the test result is negative (a), this is reported as
such in both proposals. If only a cytoplasmic staining is observed (b),
the result is reported as ANA positive in proposal 1 and as ANA
negative in proposal 2. The items positive and negative are
highlighted to emphasize the difference in the proposals. In both
proposals this result is followed by the statement of the cytoplasmic
pattern and antibody level (titer). If a combination of nuclear and
cytoplasmic patterns is observed (c), the result is reported as positive
in both proposals because of the nuclear staining. According to the
rule that patterns are reported in the sequence nuclear—cytoplas-
mic—mitotic, irrespective of the antibody level, the nuclear pattern is
mentioned first even when the antibody level of the cytoplasmic
pattern is higher. If a combination of different nuclear patterns is
observed (d), the nuclear pattern with the highest antibody level is to
be reported first. The advice to the clinician may be similar for the
respective situations in both proposals. The lay-out of the report can
be adjusted to be compatible with the local hospital information
system
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The item ‘‘type of assay’’ should specify the method used,
i.e., IIF on HEp-2 cells or alternative HEp-2 substrates,
addressable-laser bead immuno-assay (ALBIA), enzyme-
linked immunosorbent assay (ELISA), etc. Providing also
the name of the assay kit manufacturer is considered
important because it is known that some autoantibodies and
their respective patterns show-up preferentially in some
HEp-2 slide brands, such as anti-SS-A/Ro60 on HEp-2000
substrates and the anti-rods and rings pattern [11, 24]. It
was felt, however, that such information is not relevant for
the majority of patterns and autoantibodies.
The second item of the report should contain informa-
tion on the ANA test being positive or negative, the IIF
pattern, and the autoantibody titer. The results should be
reported in the sequence: positive/negative—pattern—titer.
Evidently, reporting an ANA pattern as a test result only
applies to ANA IIF results on HEp-2 cells. The nomen-
clature for ANA patterns should be according the consen-
sus reached in the first ICAP workshop [11]. The
autoantibody level can be expressed as titer, fluorescence
intensity as being generated by automated digital ANA
reading devices, or arbitrary units obtained by alternative
ANA assays. The two proposals differ in the assignment of
positive/negative because, in contrast to the first proposal,
in the second proposal, cytoplasmic and mitotic ANA
patterns are considered ANA negative. In case of mixed
patterns, all nuclear patterns are reported first and next
cytoplasmic, and then mitotic patterns. Each pattern is
directly followed with the respective titer. Within each
category, i.e., nuclear, cytoplasmic, and mitotic, the pattern
with the highest titer is mentioned first. In the second
proposal a sample with an exclusively cytoplasmic pattern
is reported as negative (with statement of the cytoplasmic
pattern and titer), whereas a sample with mixed nuclear and
cytoplasmic pattern is reported as ANA positive. Examples
for reporting distinct test results are provided in Fig. 1.
The third item of the report, addressing advice for reflex
testing in the clinical context, is similar in both proposals.
It was strongly advised against providing clinical associa-
tions. It was concluded in a separate ICAP discussion,
prepared by Minoru Satoh (Japan) and Jan Damoiseaux
(The Netherlands), that the clinical associations with ANA
patterns are poorly defined. At best, the patterns hint at the
antigens recognized and merely the cognate autoantibodies
are associated with certain diseases or manifestations of
diseases. There is no consensus yet regarding the use of
general remarks, like ‘‘ANA must be interpreted according
to the clinical picture’’ or ‘‘10 % of normal persons may
have a positive result’’ to enable better interpretation of the
test results. Further information on interpretation of the test
results obtained, however, is considered to be important.
The clearly desired goal is to inevitably develop consensus
on the content of this information.
Pros and cons for considering cytoplasmic
and mitotic patterns as ANA positive
First of all, it is important to recognize that the ICAP
discussion on how to report cytoplasmic and mitotic pat-
terns was not just a semantic discussion. As already men-
tioned, it is widely accepted that the IIF test on HEp-2 cells
enables the detection of both nuclear and non-nuclear
reactivity. Changing the name of the test to something
other than ANA might, for instance, impact on reim-
bursement policies in several jurisdictions and, therefore,
was considered not feasible at this point of time. Interest-
ingly, both the ACR and EASI/IUIS recommendations
allow the use of alternative techniques for ANA detection
[6, 8]. When applying these alternative immunoassays,
however, there appears to be no discussion on the fact that
these tests also may reveal a positive result based on the
reactivity towards (clinically relevant) non-nuclear
autoantigens, for instance Jo-1 or ribosomal P protein. To
be consistent with these alternative techniques, this may be
used as an argument to also consider cytoplasmic and
mitotic patterns as ANA positive. The most important
argument for reporting cytoplasmic patterns as ANA pos-
itive is the overall acceptance by the ICAP participants as
well as the literature that cytoplasmic patterns are clinically
relevant [5, 8, 11, 26]. If such a pattern is reported as
negative, the additional information in the report on pattern
and titer may go unnoticed because clinicians tend to pay
less attention to negative results. In Brazil, cytoplasmic
patterns have been reported as ANA positive for more than
a decade [9]. This has not raised any complaints from
either the laboratory or the clinical perspective. An
important adjustment that has been implemented in the
report of ANA results is the use of a subtitle of the ANA
test indicating that the results include more than just the
nuclear ANA patterns.
On the other hand, there were also strong arguments
against reporting cytoplasmic and/or mitotic patterns as
ANA positive. First, from the scientific point of view ANA
are defined as autoantibodies directed against nuclear
antigens. Second, ANA are included in diagnostic and/or
classification criteria for systemic lupus erythematosus
(SLE), Sjo¨gren’s syndrome, mixed connective tissue dis-
ease (MCTD), systemic sclerosis (SSc), and autoimmune
hepatitis (AIH) [27–35]. In case of SLE, both in the ACR
as well as in the more recent SLICC criteria, a positive
ANA test is an important hallmark of the disease [27, 28].
While in the 1982 ACR criteria it is explicitly stated that
ANA are to be determined by IIF, no details are provided
either in the revised ACR or the SLICC criteria about the
interpretation of cytoplasmic and mitotic patterns. Simi-
larly, in the criteria for the Sjo¨gren’s syndrome and MCTD,
critical results are defined on the ANA titer, indicating that
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IIF is the method of choice [29, 30]. Although it is antic-
ipated that the ANA mentioned in the criteria only con-
cerns true nuclear reactivity, none of the AARD criteria,
except for the SSc criteria that entail the centromere pat-
tern, has defined which IIF patterns are to be considered
positive. Obviously, by defining cytoplasmic and mitotic
patterns as ANA positive, test characteristics will change
and influence the validity of the criteria. It should be noted,
though, that the AARD criteria mentioned are all classifi-
cation criteria, which are distinct from diagnostic criteria
[36]. The criteria for AIH, however, are diagnostic criteria
[33–35]. These criteria are linked to a consensus on the
detection of autoantibodies in the autoimmune liver dis-
eases [37]. Although it is stated that for AIH an ANA test is
to be performed by IIF, it is speculated that in the future
more refined techniques using other immuno-assay formats
may enable identification of reactants and assessment of
their use for diagnosis of AIH [37]. It is evident from these
criteria, however, that only nuclear patterns are to be
interpreted as ANA positive. This is best illustrated by the
extended AIH criteria [33, 35] in which a diagnosis of AIH
is based on a scoring system. Parameters positively asso-
ciated with AIH reveal positive scores, while parameters
that direct towards other diagnoses reveal negative scores.
As such, a positive ANA may give, depending on the titer,
up to 3 points. On the other hand, the presence of anti-
mitochondrial antibodies gives a negative score of 4 points.
Obviously, this scoring system goes wrong if the cyto-
plasmic reactivity of anti-mitochondrial antibodies is
reported as ANA positive. A third argument against
reporting cytoplasmic patterns as ANA positive concerns
external quality control (EQC) programs. Indeed, some
EQC providers, like UK-NEQAS, require that a cytoplas-
mic pattern is reported as ANA negative in order to have a
full score in the EQC assessment. Obviously, if worldwide
consensus on ANA reporting can be achieved, this will
inevitably result in adjustment of the EQC scoring.
When considering these arguments, however, one
should keep in mind that a long history of technical and
scientific evolution regularly reshapes and optimizes reg-
ulations and classifications. Therefore, concerns with
reimbursement, classification criteria and EQC programs
might be considered as relative arguments, since recom-
mendations from an international board of specialists, such
as the ICAP, should be able to foster sound and relevant
update regarding the interests of all involved stakeholders.
Altogether, the discussion on cytoplasmic and mitotic
patterns has not yet reached consensus. Members of the
ICAP acknowledged that further discussion is needed for
reflection and maturation of this issue. It is anticipated that
summarizing the current status of the discussion will be of
help to come to a widely accepted consensus.
Conclusions
The clinical value of ANA testing for AARD and
autoimmune liver diseases is beyond doubt, but harmo-
nization of reporting ANA test results still needs a few
hurdles to take. The current report on the ICAP discussion
on reporting of ANA test results, and in particular the issue
of cytoplasmic and mitotic patterns being ANA positive or
negative, illustrates the intertwining of diagnostic/classifi-
cation criteria for distinct diseases associated with ANA,
methodologic consensus statements, semantic issues, as
well as political issues like reimbursement policies and
hedging for legal claims. What is needed is a paradigm
shift to get out of a vicious circle. The question is, though,
where to start? Obviously, the name of the test appears not
to be the biggest hurdle. For the time being, there is
agreement that the community can live with a misnomer,
eventually extended by a subtitle that gives credit to the
fact that also non-nuclear autoantibodies can be detected.
For alignment of methodological consensus statements,
like ICAP and diagnostic/classification criteria, there is a
need for close collaboration with the clinical parties that
are responsible for the respective criteria. This will create
mutual understanding of, and eventually a solution to, the
current dichotomy with respect to the interpretation of
cytoplasmic and mitotic patterns. If a consensus between
all stakeholders is achieved and consistently applied in the
relevant documents, there will be a strong motive to also
solve the jurisdictional issues and eventually the nomen-
clature. Full integration of this paradigm shift in the
(medical) community will require a transition period in
order to facilitate the requested adaptations.
With respect to the interpretation of the test results
obtained and the possible advice provided to the clinician,
there was consensus that information on the antigens pos-
sibly recognized as based on the ANA pattern was more
relevant than information on the possible disease associa-
tion. In the end, a laboratory test is only useful if requested
in the appropriate clinical context. It was suggested that for
standardization purposes it would be helpful to prepare
examples of these advices for each distinct ANA pattern,
preferentially in relation to the clinical information pro-
vided alongside the ANA request. These advices should be
made available on the ICAP website (http://www.anapat
terns.org). If pattern and antigen-specificity are concordant,
this will also increase the clinical value of the combined
laboratory result.
Altogether, the activity of the ICAP initiative has been
very successful in bringing up and disseminating the
importance of the correct identification and denomination
of the various IIF patterns observable in the ANA-HEp-2
test. The discussion on reporting of ANA results upheld
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during the second ICAP has pinpointed additional issues
that need to be addressed in forthcoming ICAP workshops.
Acknowledgments The authors thank the German Association of
Clinical Chemistry and Laboratory Medicine (DGKL e. V.) for
sponsoring the 2nd ICAP workshop in Dresden. Furthermore, we
thank all participants of the 2nd ICAP workshop for their valuable
contribution to the discussion. In particular, we thank Nicola Bizzaro
(Italy), Xavier Bossuyt (Belgium), Pier-Luigi Meroni (Italy), and
Johan Ro¨nnelid for additional input on this topic.
Compliance with ethical standards
Conflict of interest MF has honoraria and consultation (INOVA
Diagnostics Inc and Euroimmun GmbH). Other authors have none.
Ethical approval This article does not contain any studies with
human participants or animals performed by any of the authors.
Informed consent This article does not contain any studies with
human participants performed by any of the authors and therefore
informed consent is not applicable.
References
1. Solomon DH, Kavanaugh AJ, Schur PH (2002) Evidence-based
guidelines for the use of immunologic tests: antinuclear antibody
testing. Arthritis Rheum 47:434–444
2. Mahler M, Fritzler MJ (2012) The clinical significance of the
dense fine speckled immunofluorescence pattern on HEp-2 cells
for the diagnosis of systemic autoimmune diseases. Clin Dev
Immunol 2012:494356
3. Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK (2015) A
Comprehensive overview on myositis-specific antibodies: new
and old biomarkers in idiopathic inflammatory myopathy. Clin
Rev Allergy Immunol. doi:10.1007/s12016-015-8510-y
4. Coons AH, Kaplan MH (1950) Localization of antigen in tissue
cells; improvements in a method for the detection of antigen by
means of fluorescent antibody. J Exp Med 91:1–13
5. Mahler M, Meroni PL, Bossuyt X, Fritzler MJ (2014) Current
concepts and future directions for the assessment of autoanti-
bodies to cellular antigens referred to as anti-nuclear antibodies.
J Immunol Res 2014:315179
6. Meroni PL, Schur PH (2010) ANA screening: an old test with
new recommendations. Ann Rheum Dis 69:1420–1422
7. Fritzler MJ (2011) The antinuclear antibody (ANA) test: last or
lasting gasp? Arthritis Rheum 16:19–22
8. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T,
Herold M et al (2014) International recommendations for the
assessment of autoantibodies to cellular antigens referred to as
anti-nuclear antibodies. Ann Rheum Dis 73:17–23
9. Dellavance A, Junior AG, Cintra AFU, Ximenes AC, Nuccitelli
B, Taliberti BH et al (2003) Brazilian consensus on antinuclear
antibodies in HEp-2 cells. Definitions for standardization of
autoantibody testing against the nucleus (ANA HEP-2), nucleo-
lus, cytoplasm and mitotic apparatus, as well as its clinical
associations. Rev Bras Reumatol 43:129–140
10. Damoiseaux J, Andrade LE, Fritzler MJ, Shoenfeld Y (2015)
Autoantibodies 2015: from diagnostic biomarkers toward pre-
diction, prognosis and prevention. Autoimmun Rev 14:555–563
11. Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo
Cruvinel W, Francescantonio PL et al (2015) Report of the first
international consensus on standardized nomenclature of
antinuclear antibody HEp-2 cell patterns 2014–2015. Front
Immunol 6:412
12. Sack U, Conrad K, Csernok E, Frank I, Hiepe F, Krieger T et al
(2009) Autoantibody detection using indirect immunofluores-
cence on HEp-2 cells. Ann NY Acad Sci 1173:166–173
13. Damoiseaux J, Bakker-Jonges L, Cohen Tervaert JW, Derksen R,
Hooijkaas H, Kallenberg C et al (2010) Laboratory diagnosis of
ANA, anti-ds-DNA- and anti- ENA-antibodies: recommendation
following the outcomes of a questionnaire. Ned Tijdschr Klin
Chem Labgeneesk 35:234–239
14. Francescantonio PL, de Melo Cruvinel W, Dellavance A,
Andrade LE, Taliberti BH et al (2014) IV Brazilian guidelines for
autoantibodies on HEp-2 cells. Rev Bras Reumatol 54:44–50
15. Yazdany J, Schmajuk G, Robbins M, Daikh D, Beall A, Yelin E
et al (2013) Choosing wisely: the American College of
Rheumatology’s top 5 list of things physicians and patients
should question. Arthritis Care Res Hoboken 65:329–339
16. Van Blerk M, Bossuyt X, Humbel R, Mewis A, Servais G,
Tomasi JP et al (2014) Belgian recommendations on ANA, anti-
dsDNA and anti-ENA antibody testing. Acta Clin Belg 69:83–86
17. Herold M, Klotz W, Demel U, Endler G, Forster E, Griesmacher
A et al (2015) International consensus on ANA determination—
what changes in the German-speaking area? Laboratori-
umsMedizin 39:145–152
18. Carballo OG, Ingenito FB, Ginaca AA, Carabajal P, Costa MA,
Balbaryski J (2012) First Argentine consensus for standardization
of antinuclear antibodies by indirect immunofluorescence-HEp-2.
Acta Bioquı´m Clı´n Latinoam 46:3–13
19. Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A,
Andrade LE (2011) ANA-HEp-2 pattern is a critical parameter for
discriminating ANA-positive healthy individuals and patients with
autoimmune rheumatic diseases. Arthritis Rheum 63:191–200
20. Op De Beeck K, Vermeersch P, Verschueren P, Westhovens R,
Marie¨n G, Blockmans D et al (2011) Detection of antinuclear
antibodies by indirect immunofluorescence and by solid phase
assay. Autoimmun Rev 10:801–808
21. Bossuyt X, Hendrickx A, Frans J (2005) Antinuclear antibody
titer and antibodies to extractable nuclear antigens. Arthritis
Rheum 53:987–988
22. Damoiseaux JG, Tervaert JW (2006) From ANA to ENA: how to
proceed? Autoimmun Rev 5:10–17
23. Bonroy C, Verfaillie C, Smith V, Persijn L, De Witte E, De
Keyser F et al (2013) Automated indirect immunofluorescence
antinuclear antibody analysis is a standardized alternative for
visual microscope interpretation. Clin Chem Lab Med
51:1771–1779
24. Schouwers S, Bonnet M, Verschueren P, Westhovens R, Block-
mans D, Marie¨n G et al (2014) Value-added reporting of antin-
uclear antibody testing by automated indirect
immunofluorescence analysis. Clin Chem Lab Med 52:547–551
25. Fritzler MJ, Hanson C, Miller J, Eystathioy T (2002) Specificity
of autoantibodies to SS-A/Ro on a transfected and overexpressed
human 60 kDa Ro autoantigen substrate. J Clin Lab Anal
16:103–108
26. Wiik AS, Hoier-Madsen M, Forslid J, Charles P, Meyrowitsch J
(2010) Antinuclear antibodies: a contemporary nomenclature
using HEp-2 cells. J Autoimmun 35:276–290
27. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield
NF et al (1982) The 1982 revised criteria for the classification of
systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
28. Petri M, Orbai AM, Alarco´n GS, Gordon C, Merrill JT, Fortin PR
et al (2012) Derivation and validation of the Systemic Lupus
International Collaborating Clinics classification criteria for sys-
temic lupus erythematosus. Arthritis Rheum 64:2677–2686
29. Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S,
Lanfranchi H et al (2012) American College of Rheumatology
Autoimmun Highlights (2016) 7:1 Page 7 of 8 1
123
classification criteria for Sjo¨gren’s syndrome: a data-driven,
expert consensus approach in the Sjo¨gren’s International Col-
laborative Clinical Alliance cohort. Arthritis Care Res
64:475–487
30. Amigues JM, Cantagrel A, Abbal M, Mazieres B (1996) Com-
parative study of 4 diagnosis criteria sets for mixed connective
tissue disease in patients with anti-RNP antibodies. Autoimmu-
nity Group of the Hospitals of Toulouse. J Rheumatol
23:2055–2062
31. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M,
Tyndall A et al (2013) 2013 classification criteria for systemic
sclerosis: an American College of Rheumatology/European
League against Rheumatism collaborative initiative. Arthritis
Rheum 65:2737–2747
32. Meroni PL, Biggioggero M, Pierangeli SS, Sheldon J, Zegers I,
Borghi MO (2014) Standardization of autoantibody testing: a
paradigm for serology in rheumatic diseases. Nat Rev Rheumatol
10:35–43
33. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK,
Cancado EL et al (1999) International Autoimmune Hepatitis
Group Report: review of criteria for diagnosis of autoimmune
hepatitis. J Hepatol 31:929–938
34. Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt
EL et al (2008) Simplified criteria for the diagnosis of autoim-
mune hepatitis. Hepatology 48:169–176
35. Liberal R, Grant CR, Longhi MS, Mieli-Vergani G, Vergani D
(2014) Diagnostic criteria of autoimmune hepatitis. Autoimmun
Rev 13:435–440
36. Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller
A et al (2015) Distinctions Between Diagnostic and Classification
Criteria? Arthritis Care Res Hoboken 67:891–897
37. Vergani D, Alvarez F, Bianchi FB, Cancado EL, Mackay IR,
Manns MP et al (2004) Liver autoimmune serology: a consensus
statement from the committee for autoimmune serology of the
International Autoimmune Hepatitis Group. J Hepatol
41:677–683
1 Page 8 of 8 Autoimmun Highlights (2016) 7:1
123
